Vanda rises after FDA grants rare hearing on jet‑lag drug bid

Shares of drugmaker Vanda Pharmaceuticals VNDA.O rise 2.2% to $8.35 premarket

Company says FDA will hold a rare public hearing to review its bid to expand sleep drug Hetlioz for jet‑lag disorder

Jet lag occurs when long‑distance travel disrupts the body’s internal clock, causing fatigue and poor sleep

VNDA says this is the first such drug‑approval hearing in more than 40 years and follows its appeal after FDA initially refused the application

Hetlioz is already approved for two rare sleep disorders

VNDA shares up ~84% in 2025